<- Go Home
RayzeBio, Inc.
RayzeBio, Inc. develops radiopharmaceutical therapeutics for the treatment of cancer. The company was incorporated in 2020 and is based in San Diego, California. As of February 26, 2024, RayzeBio, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.
Market Cap
$3.7B
Volume
785.8K
Cash and Equivalents
$252.0M
EBITDA
-$73.9M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$62.51
52 Week Low
$17.95
Dividend
N/A
Price / Book Value
6.50
Price / Earnings
-7.13
Price / Tangible Book Value
6.50
Enterprise Value
$3.2B
Enterprise Value / EBITDA
-45.36
Operating Income
-$75.7M
Return on Equity
N/A
Return on Assets
N/A
Cash and Short Term Investments
$540.2M
Debt
$9.7M
Equity
$575.3M
Revenue
N/A
Unlevered FCF
N/A
Sector
Biotechnology
Category
N/A